FDA Inspection 1271693 — Cooperman Barnabas Medical Center Inc.
The FDA completed an inspection of Cooperman Barnabas Medical Center Inc. on June 2, 2025 in Livingston, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- June 2, 2025
- Fiscal Year
- 2025
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Livingston, NJ (United States)